These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34299478)

  • 1. A Novel Calcium-Dependent Protein Kinase 1 Inhibitor Potently Prevents
    Débare H; Moiré N; Baron F; Lantier L; Héraut B; Van Langendonck N; Denevault-Sabourin C; Dimier-Poisson I; Debierre-Grockiego F
    Molecules; 2021 Jul; 26(14):. PubMed ID: 34299478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1 decrease the parasite burden in mice with acute toxoplasmosis.
    Moine E; Moiré N; Dimier-Poisson I; Brunet K; Couet W; Colas C; Van Langendonck N; Enguehard-Gueiffier C; Gueiffier A; Héraut B; Denevault-Sabourin C; Debierre-Grockiego F
    Int J Parasitol; 2018 Jun; 48(7):561-568. PubMed ID: 29524527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1.
    Moine E; Dimier-Poisson I; Enguehard-Gueiffier C; Logé C; Pénichon M; Moiré N; Delehouzé C; Foll-Josselin B; Ruchaud S; Bach S; Gueiffier A; Debierre-Grockiego F; Denevault-Sabourin C
    Eur J Med Chem; 2015 Nov; 105():80-105. PubMed ID: 26479029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice.
    Chen J; Li ZY; Huang SY; Petersen E; Song HQ; Zhou DH; Zhu XQ
    BMC Infect Dis; 2014 Sep; 14():487. PubMed ID: 25192845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.
    Vidadala RS; Rivas KL; Ojo KK; Hulverson MA; Zambriski JA; Bruzual I; Schultz TL; Huang W; Zhang Z; Scheele S; DeRocher AE; Choi R; Barrett LK; Siddaramaiah LK; Hol WG; Fan E; Merritt EA; Parsons M; Freiberg G; Marsh K; Kempf DJ; Carruthers VB; Isoherranen N; Doggett JS; Van Voorhis WC; Maly DJ
    J Med Chem; 2016 Jul; 59(13):6531-46. PubMed ID: 27309760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metacytofilin Is a Potent Therapeutic Drug Candidate for Toxoplasmosis.
    Leesombun A; Iijima M; Umeda K; Kondoh D; Pagmadulam B; Abdou AM; Suzuki Y; Ohba SI; Isshiki K; Kimura T; Kubota Y; Sawa R; Nihei CI; Nishikawa Y
    J Infect Dis; 2020 Feb; 221(5):766-774. PubMed ID: 31573038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum.
    Winzer P; Müller J; Aguado-Martínez A; Rahman M; Balmer V; Manser V; Ortega-Mora LM; Ojo KK; Fan E; Maly DJ; Van Voorhis WC; Hemphill A
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6361-74. PubMed ID: 26248379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors.
    Ojo KK; Larson ET; Keyloun KR; Castaneda LJ; Derocher AE; Inampudi KK; Kim JE; Arakaki TL; Murphy RC; Zhang L; Napuli AJ; Maly DJ; Verlinde CL; Buckner FS; Parsons M; Hol WG; Merritt EA; Van Voorhis WC
    Nat Struct Mol Biol; 2010 May; 17(5):602-7. PubMed ID: 20436472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Live Attenuated Pru:Δcdpk2 Strain of Toxoplasma gondii Protects Against Acute, Chronic, and Congenital Toxoplasmosis.
    Wang JL; Li TT; Elsheikha HM; Chen K; Cong W; Yang WB; Bai MJ; Huang SY; Zhu XQ
    J Infect Dis; 2018 Jul; 218(5):768-777. PubMed ID: 29669003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxoplasmosis in pregnancy: prevention, screening, and treatment.
    Paquet C; Yudin MH;
    J Obstet Gynaecol Can; 2013 Jan; 35(1):78-81. PubMed ID: 23343802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplacental toxoplasmosis in naturally-infected white-tailed deer: Isolation and genetic characterisation of Toxoplasma gondii from foetuses of different gestational ages.
    Dubey JP; Velmurugan GV; Ulrich V; Gill J; Carstensen M; Sundar N; Kwok OC; Thulliez P; Majumdar D; Su C
    Int J Parasitol; 2008 Jul; 38(8-9):1057-63. PubMed ID: 18187136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and validation of a guinea pig model for human congenital toxoplasmosis.
    Grochow T; Beck B; Rentería-Solís Z; Schares G; Maksimov P; Strube C; Seeger J; Raqué L; Ulrich R; Daugschies A; Fietz SA
    Parasit Vectors; 2021 Aug; 14(1):389. PubMed ID: 34362413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocysts.
    Imhof D; Anghel N; Winzer P; Balmer V; Ramseier J; Hänggeli K; Choi R; Hulverson MA; Whitman GR; Arnold SLM; Ojo KK; Van Voorhis WC; Doggett JS; Ortega-Mora LM; Hemphill A
    Int J Parasitol Drugs Drug Resist; 2021 Aug; 16():90-101. PubMed ID: 34030110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of PERK eIF2α Kinase Inhibitor against Toxoplasma gondii.
    Augusto L; Martynowicz J; Staschke KA; Wek RC; Sullivan WJ
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181373
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis.
    Müller J; Aguado-Martínez A; Ortega-Mora LM; Moreno-Gonzalo J; Ferre I; Hulverson MA; Choi R; McCloskey MC; Barrett LK; Maly DJ; Ojo KK; Van Voorhis W; Hemphill A
    J Antimicrob Chemother; 2017 Aug; 72(8):2334-2341. PubMed ID: 28486633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mic1-3 knockout of Toxoplasma gondii is a successful vaccine against chronic and congenital toxoplasmosis in mice.
    Ismael AB; Dimier-Poisson I; Lebrun M; Dubremetz JF; Bout D; Mevelec MN
    J Infect Dis; 2006 Oct; 194(8):1176-83. PubMed ID: 16991094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity.
    Johnson SM; Murphy RC; Geiger JA; DeRocher AE; Zhang Z; Ojo KK; Larson ET; Perera BG; Dale EJ; He P; Reid MC; Fox AM; Mueller NR; Merritt EA; Fan E; Parsons M; Van Voorhis WC; Maly DJ
    J Med Chem; 2012 Mar; 55(5):2416-26. PubMed ID: 22320388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of vertical transmission of Toxoplasma gondii in Calomys callosus model after reinfection with heterologous and virulent strain.
    Franco PS; Silva DA; Costa IN; Gomes AO; Silva AL; Pena JD; Mineo JR; Ferro EA
    Placenta; 2011 Feb; 32(2):116-20. PubMed ID: 21146211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of protective immunity induced by recombinant calcium-dependent protein kinase 1 (TgCDPK1) protein against acute toxoplasmosis in mice.
    Huang SY; Chen K; Wang JL; Yang B; Zhu XQ
    Microb Pathog; 2019 Aug; 133():103560. PubMed ID: 31145981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of ursolic acid derivatives with potential anti-Toxoplasma gondii activity.
    Zhang LH; Jin LL; Liu F; Jin C; Jin CM; Wei ZY
    Exp Parasitol; 2020 Sep; 216():107935. PubMed ID: 32569599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.